ArticlePrecision clinical medicine2025
Citrullination of CAMP exacerbating mucosal inflammation in inflammatory bowel disease.
Article in Precision clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Risk of Inflammatory Bowel Disease Following Hospital-Treated Infections and Modulatory Role of Host Genetics to Support a Multi-Hit Pathogenesis Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Decoding the gut microbiota-immune dialogue: from bidirectional axis to therapeutic applications.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cathelicidin (CAMP), plays important roles in pathogen defense, immune regulation, and epithelial barrier maintenance. While previous studies have highlighted its protective function, the post-translational modifications and downstream immune-metabolic effects of CAMP in the pathogenesis of inflammatory bowel disease remain unclear. Methods: A dextran sodium sulfate (DSS)-induced colitis mouse model was employed to assess the role of CAMP and its citrullination mediated by peptidyl arginine deiminase 4 (PAD4). Proteomic and metaproteomic analyses were performed to investigate microbiota composition and functional shifts. We generated gene-deficient mouse models, CAMP knockout (KO) and PAD4-KO mice, to dissect molecular mechanisms. Epithelial integrity, inflammatory markers, and immune responses have been evaluated at both the protein and mRNA levels. Bone marrow-derived dendritic cells and primary CD4⁺ T cells were co-cultured to examine the effects of CAMP-related metabolites on antigen presentation and Th17 differentiation. Furthermore, we evaluated the impact of CAMP peptide supplementation and the effects of CAMP-KO mice on DSS-induced colitis. Results: CAMP citrullination was significantly elevated in DSS-induced colitis mice but restored by PAD4 deletion. Citrullination was found to reduce CAMP protein levels without affecting its transcriptional expression. The absence of CAMP exacerbated intestinal inflammation in DSS-treated mice. Metaproteomic analysis identified 70 differentially expressed proteins and 15 altered microbiota families associated with CAMP deficiency. Elevated levels of arginase-1 and its metabolites, particularly polyamines, enhanced dendritic cell maturation and increased Th17 polarization in CAMP-KO mice. Conclusions: Our findings highlight that the protein level of CAMP decreased after PAD4-mediated citrullination, thus playing a vital role in regulating taxonomic community structure, restricting arginine metabolism, and regulating dendritic cell-Th17 immune responses in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.